Education
About Us
Working with TipRanks
Follow Us
SAWAI GROUP HOLDINGS Co., Ltd. (JP:4887)
:4887
4887 Stock Chart & Stats
¥2359.00
-¥48.50(-2.23%)
At close: 4:00 PM EST
¥2359.00
-¥48.50(-2.23%)
Day’s Range― - ―
52-Week Range¥1,650.00 - ¥2,447.00
Previous CloseN/A
Volume473.80K
Average Volume (3M)299.27K
Market Cap
¥225.45B
Enterprise Value¥329.39B
Total Cash (Recent Filing)¥46.12B
Total Debt (Recent Filing)¥122.49B
Price to Earnings (P/E)13.9
Beta0.32
Next Earnings
May 13, 2026EPS Estimate
26.49Next Dividend Ex-DateN/A
Dividend Yield2.28%
Share Statistics
EPS (TTM)42.46
Shares Outstanding115,487,140
10 Day Avg. Volume288,420
30 Day Avg. Volume299,266
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)1.30
P/FCF Ratio33.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,250.00Price Target Upside-4.62% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)122.62
Revenue Forecast (FY)¥204.58B
Bulls Say, Bears Say
Bulls Say
Top-line MomentumSawai’s +34% TTM revenue growth reflects durable demand for its generic portfolio and successful product mix expansion. Sustained top-line growth supports scale benefits, maintains bargaining power with distributors, and provides a foundation for reinvestment in R&D and manufacturing capacity over the next 2–6 months.
Cash GenerationPositive operating cash flow (¥20.3B TTM) and FCF (¥5.8B) indicate the business converts sales into cash, supporting operational continuity, dividend payments, and selective capital spending. Even with volatility, recurring cash generation gives management flexibility to fund growth or deleverage.
Balance-sheet Equity CushionA sizable equity base relative to assets provides a durable capital cushion against sector shocks and supports investment in manufacturing and regulatory compliance. This balance-sheet depth underpins creditworthiness and long-term operational stability despite cyclical pressures.
Bears Say
Margin CompressionA material fall in net margin from ~12.1% to ~4.9% erodes earnings power and indicates structural pressure on profitability—likely from pricing, cost inflation or mix changes. Persistently lower margins reduce internally available funds for reinvestment and weaken long-term return prospects.
Volatile Free Cash FlowFCF volatility and recent decline signal that earnings do not reliably convert to discretionary cash. This unpredictability limits the company’s ability to plan capex, acquisitions, or consistent dividends and increases refinancing and operational risk over a multi‑quarter horizon.
Rising Leverage & Weaker ROEIncreased leverage reduces financial flexibility and raises interest and refinancing exposure, while a falling ROE shows diminished returns on shareholders’ capital. Together these trends constrain the company’s ability to fund growth organically and amplify downside in an adverse revenue or margin environment.
SAWAI GROUP HOLDINGS Co., Ltd. News
4887 FAQ
What was SAWAI GROUP HOLDINGS Co., Ltd.’s price range in the past 12 months?
SAWAI GROUP HOLDINGS Co., Ltd. lowest stock price was ¥1650.00 and its highest was ¥2447.00 in the past 12 months.
What is SAWAI GROUP HOLDINGS Co., Ltd.’s market cap?
SAWAI GROUP HOLDINGS Co., Ltd.’s market cap is ¥225.45B.
When is SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date?
SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date is May 13, 2026 which is in 68 days.
How were SAWAI GROUP HOLDINGS Co., Ltd.’s earnings last quarter?
SAWAI GROUP HOLDINGS Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥42.46 earnings per share for the quarter, missing the consensus estimate of ¥58.03 by -¥15.57.
Is SAWAI GROUP HOLDINGS Co., Ltd. overvalued?
According to Wall Street analysts SAWAI GROUP HOLDINGS Co., Ltd.’s price is currently Overvalued.
Does SAWAI GROUP HOLDINGS Co., Ltd. pay dividends?
SAWAI GROUP HOLDINGS Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.28%. See more information on SAWAI GROUP HOLDINGS Co., Ltd. dividends here
What is SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate?
SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate is 26.49.
How many shares outstanding does SAWAI GROUP HOLDINGS Co., Ltd. have?
SAWAI GROUP HOLDINGS Co., Ltd. has 115,487,140 shares outstanding.
What happened to SAWAI GROUP HOLDINGS Co., Ltd.’s price movement after its last earnings report?
SAWAI GROUP HOLDINGS Co., Ltd. reported an EPS of ¥42.46 in its last earnings report, missing expectations of ¥58.03. Following the earnings report the stock price went down -4.582%.
Which hedge fund is a major shareholder of SAWAI GROUP HOLDINGS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4887
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
4887 Stock 12 Month Forecast
Average Price Target
¥2,250.00
▼(-4.62% Downside)
Technical Analysis
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---